Wound Healing

Educational Notice

Peptidings provides information for educational and research purposes only. The peptides discussed on this page are subjects of ongoing scientific research. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.

Browse by Condition

Wound Healing

Wound healing is one of the more biologically coherent areas of peptide research, and several compounds here have mechanistic cases that are genuinely well-developed in the preclinical literature. The challenge is the same as in most other categories: animal wound models translate poorly to human clinical outcomes, and the step from promising rodent data to a completed Phase II trial in humans has rarely been taken. GHK-Cu is the partial exception—decades of topical cosmetic use data exist, though route of administration remains a significant variable.

Evidence Tiers:
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
It’s Complicated

Compounds with Research Relevant to Wound Healing

Each compound links to its full pillar article. The most useful sections for evaluating a specific application are the Claims vs. Evidence table and the Safety, Risks, and Limitations section. Evidence tiers reflect the strongest available data for a compound overall—not necessarily for this specific application.

Pilot Data
WADA

BPC-157: What the Research Says about This Pentadecapeptide

Gastric pentadecapeptide studied for tissue repair, tendon healing, and gut protection. Pilot human data only; WADA prohibited.

Read the research →

It's Complicated

GHK-Cu: What the Research Says about the Copper Peptide

Copper-binding tripeptide studied for wound healing, collagen synthesis, and skin remodeling. Evidence varies significantly by route of administration.

Read the research →

Preclinical

KPV (Lysine-Proline-Valine): Research Overview

C-terminal alpha-MSH tripeptide studied for anti-inflammatory effects in gut and wound models. Preclinical evidence only.

Read the research →

Preclinical

LL-37 (Cathelicidin): What the Research Shows

The only human cathelicidin, studied for antimicrobial activity and wound healing. Preclinical evidence only.

Read the research →

Preclinical
WADA

TB-500: What the Research Says about Thymosin Beta-4’s Synthetic Fragment

Synthetic Thymosin Beta-4 fragment studied for tissue repair and cell migration. Preclinical evidence only; WADA prohibited.

Read the research →

Clinical Trials
WADA

Thymosin Beta-4: What the Research Shows

Endogenous 43-amino acid actin-sequestering peptide studied for wound healing, cardiac repair (RGN-352 Phase II), and corneal regeneration (RGN-259). TB-500 is its synthetic fragment — distinct compounds.

Read the research →

Research Cluster

These compounds are covered in depth in the Injury Recovery and Tissue Repair cluster hub.

Browse the Cluster →

Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.

Scroll to Top